TrialFind
Saved trials
Back to results
Completed
Phase 1
Phase 2
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
NCT02041429
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
View on ClinicalTrials.gov
Official details
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca — TrialFind